Sentara Hospitals

SeaStar Medical activates Sentara Norfolk General Hospital as its 13th site in the NEUTRALIZE-AKI trial, enrolling 65 AKI patients. The trial evaluates the Selective Cytopheretic Device (SCD) for safety and efficacy in 200 ICU patients on continuous renal replacement therapy (CRRT). The SCD targets hyperinflammation to reduce organ damage and dialysis dependence, with potential annual peak sales of $1 billion in the U.S. AKI market.